VYNE Therapeutics Inc. (VYNE) Tops Q3 EPS by 1c

VYNE Therapeutics Inc. (NASDAQ: VYNE) reported Q3 EPS of ($0.16), $0.01 better than the analyst estimate of ($0.17). Revenue for the quarter came in at $200 thousand versus the consensus estimate of $133.33 thousand.

For earnings history and earnings-related data on VYNE Therapeutics Inc. (VYNE) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Rein Therapeutics Inc. (RNTX) Tops Q2 EPS by 39c
• Algorhythm Holdings (RIME) Tops Q2 EPS by 54c